RNAC Stock Overview
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cartesian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.64 |
| 52 Week High | US$42.60 |
| 52 Week Low | US$11.67 |
| Beta | 0 |
| 1 Month Change | 42.36% |
| 3 Month Change | 6.62% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -29.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| RNAC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.3% | 0.5% | -0.7% |
| 1Y | n/a | 1.2% | 22.8% |
Return vs Industry: Insufficient data to determine how RNAC performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how RNAC performed against the US Market.
Price Volatility
| RNAC volatility | |
|---|---|
| RNAC Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RNAC's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RNAC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 38 | Carsten Brunn | www.cartesiantherapeutics.com |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases.
Cartesian Therapeutics, Inc. Fundamentals Summary
| RNAC fundamental statistics | |
|---|---|
| Market cap | US$402.90m |
| Earnings (TTM) | -US$257.26m |
| Revenue (TTM) | US$26.00m |
15.5x
P/S Ratio-1.6x
P/E RatioIs RNAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNAC income statement (TTM) | |
|---|---|
| Revenue | US$26.00m |
| Cost of Revenue | US$71.84m |
| Gross Profit | -US$45.83m |
| Other Expenses | US$211.43m |
| Earnings | -US$257.26m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.46 |
| Gross Margin | -176.26% |
| Net Profit Margin | -989.31% |
| Debt/Equity Ratio | 0% |
How did RNAC perform over the long term?
See historical performance and comparison